Biosynthetic pathway discoveries mean we can halve the price of costly cancer drug
Researchers have identified the enzymes responsible for the two critical final steps in the biosynthetic pathway that makes the chemotherapy drug Taxol active as a drug, potentially opening it up to biotech based production.
Registered users, subscribers or members - SIGN IN
To continue reading this article
Membership
Included as a benefit
Members of Applied Microbiology International have unlimited access to The Microbiologist as a benefit of membership. Just sign in with your usual membership credentials.
Find out more about how to join.
Register
FREE
Want to read more before deciding on a subscription? It only takes a minute to sign up for a free account and you’ll get to enjoy more free content each month.
Subscribe
3.75 per month / £35 annually
Get unlimited access to The Microbiologist.